NF1 Associated with More Cancer Types Than Previously Known
Prostate Cancer Survivor Sheds Light On Common Stigmas
Your browser is not supportedusatoday.Comusatoday.Com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use.
Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on usatoday.Com
Initial Quality Of Life Decreases After Radiation In Prostate Cancer
Treatment with a certain radiation therapy worsens quality of life in patients with prostate cancer. An expert explains ways to mitigate side effects.
Urinary and bowel functioning are side experienced after IMRT in patients with prostate cancer, an expert told CURE®.
Patients with prostate cancer who receive intensity-modulated radiation therapy (IMRT) may experience a decrease in quality of life for the first six months after treatment. However, many side effects tend to subside months later, according to an expert and recent study.
A study from Current Oncology included 391 patients with prostate cancer who were treated with IMRT. Examining patients' quality of life after finishing treatment was the purpose of the study.
The researchers determined that there was a significant decrease in quality of life right after treatment finished. Signs of worsening were seen in global health, physical, role functioning, fatigue, appetite loss, diarrhea and pain, the study noted.
Of note, patients recovered from these aspects within six months, except for physical functioning, the researchers stated. However, at five years, researchers found that patients typically had worsening physical functioning.
When patients experience impairment after IMRT, they may also have a deterioration in health-related quality of life, the researchers said.
"Generally, radiation therapy will cause some impact on urinary and bowel function and can also cause some fatigue," Dr. Arun Goel told CURE®. Goel is chief of genitourinary services in radiation oncology and assistant professor of clinical radiation oncology at Penn Medicine.
Goel explained that quality of life is evaluated through answers from surveys and questionnaires. Doctors gain "a better understanding" of patients' experiences regarding treatments and how it affects their physical or social functioning.
According to the Mayo Clinic, IMRT is a type of radiation therapy that uses beams of powerful energy to destroy cancer cells. What sets it apart from regular radiation therapy is its customized beams, which match the shape of the cancer. The intensity varies among each beam and is precisely controlled when delivered, the institution noted.
IMRT and Quality of Life in Patients With Prostate CancerPossible reasons for a temporary decrease in quality of life may be caused by traveling and worsened functioning, Goel said. "Going back and forth from a department for a number of weeks can probably lead to some fatigue."
Worsening in urinary and bowel function, Goel explained, could also be a main contributor to a decrease in quality of life.
"It's the combination of these side effects that uproot temporarily some day-to-day routines that lead to a reduction in quality of life. [The quality of life improves] once the treatments are done, side effects resolve and people [return] to their normal rhythm or role."
READ MORE: 'Paths' of Treatment Possibilities in Prostate Cancer
"What we generally see with IMRT quality of life studies is that there's some reduction in urinary and bowel quality of life at the end of treatment," he said. "These can translate into reductions in quality of life when it comes to these social functions. But thankfully, these reductions are generally pretty small. By six months, quality of life is improving back to baseline."
Side effects and quality of life "go hand in hand," Goel said. Patients who receive IMRT may mostly experience side effects related to urinary and bowel functions.
"Inflammation of the bladder and to the urethra can lead to increased urinary frequency, some urinary urgency, a weakening of the urinary stream or even some burning with urination," he noted. "It's important to say that these side effects are generally in the mild category and temporary, meaning that they can be managed with either lifestyle modifications, routine over-the-counter prescription medications. They should resolve within eight to 12 weeks after radiation therapy is completed."
Advice for Patients With Prostate Cancer Receiving IMRTIt's important for patients with prostate cancer to "stay ahead of things" after receiving IMRT, Goel said.
He emphasized that patients should speak with their nurses and doctors to continue mitigating side effects during treatment. Specifically, patients informing their care teams about bowel and urinary functioning early can help slow down these side effects.
"For certain patients, we may start medications called alpha-adrenergic blockers prophylactically," Goel said. "So those are medications like [Flomax (tamsulosin)] or [Rapaflo (silodosin)] to relax to musculature of the bladder neck, they relax the musculature of the urethra to make it easier to empty the bladder."
He also explained that other options can also help patients with side effects.
"There are both gels as well as balloons that can be inserted as an outpatient procedure under local anesthesia or mild sedation, that pushes the prostate away from the rectum, reduces rectal dose and seem to reduce the risk of having chronic rectal side effects," Goel said. "So certainly, reducing those risks should translate to improvements in quality of life."
For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.
Prostate Cancer News
Jan. 23, 2024 — Combining testosterone-blocking drugs in patients with prostate cancer relapse prevents the spread of cancer better than treatment with a single drug, a multi-institution, Phase 3 clinical trial has ...
Aug. 22, 2023 — Using MRI as a screening test alongside PSA density allowed detection of cancers that would have been missed by the blood test alone, according to new ...
Aug. 15, 2023 — Researchers demonstrate how mathematical modeling combined with dynamic biomarkers can be used to characterize metastatic disease and identify appropriate therapeutic approaches to improve patient ...
Aug. 14, 2023 — A study uncovers a new mechanism to explain why some prostate tumors switch from a common, treatable form to a more rare and aggressive form of prostate ...
Aug. 14, 2023 — Patients with localized prostate cancer have a good chance of survival, but mortality rates among those with advanced, metastatic forms of the condition remain high. Until now, the precise mechanism ...
July 19, 2023 — Three new biomarkers for prostate cancer have been identified to help pinpoint potentially aggressive cases of the disease, which kills 300,000 men each ...
July 12, 2023 — Prostate cancer is a leading cause of death among American men, and it's resistant to one of the most powerful chemotherapy medications -- cisplatin. Now, researchers have developed the first ...
Apr. 10, 2023 — A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 ...
Mar. 16, 2023 — The combination of two oral medications has shown positive results in people with prostate cancer, whose disease has spread to other parts of the body. Compared with XTANDI plus placebo, the ...
Mar. 9, 2023 — New research shows that men who stick to a predominantly Mediterranean diet are less likely to be diagnosed with prostate cancer. This diet also improves their chances of recovery if they have PC and ...
Mar. 8, 2023 — The nitrate ingested over the course of a person's adult lifetime through the consumption of tap water and bottled water could be a risk factor for prostate cancer, particularly in the case of ...
Feb. 7, 2023 — Researchers have helped develop a new blood test to detect prostate cancer with greater accuracy than current methods. New research shows that the Prostate Screening EpiSwitch (PSE) blood test is ...
Jan. 23, 2023 — Researchers discover a potential therapeutic avenue via neuronal endocrine receptors that could be helpful in battling an aggressive form of prostate ...
Jan. 12, 2023 — For men who undergo radiotherapy for localized prostate cancer, the precise targeting capabilities of MRI guidance resulted in fewer toxicities and better quality of life according to new ...
Dec. 14, 2022 — A single bout of exercise has been shown to elevate anti-cancer proteins called myokines in people with advanced prostate cancer, to levels which can significantly suppress tumour ...
Dec. 13, 2022 — Researchers have characterised prostate cancer cell dynamics at a single-cell resolution across the timespan of the disease -- from its beginning to the point of androgen independence, where the ...
Dec. 9, 2022 — Scientists have created a comprehensive tool for predicting an individual's risk of developing prostate cancer, which they say could help ensure that those men at greatest risk will receive the ...
Nov. 29, 2022 — A family history of cancer and genetic variants that might be inherited appear to be important risk factors for Black men diagnosed with early-onset prostate cancer, a study has ...
Nov. 23, 2022 — A single drug compound simultaneously attacks hard-to-treat prostate cancer on several fronts, according to a new study in mice and human cells. It triggers immune cells to attack, helps the immune ...
Nov. 13, 2022 — Researchers have found a new theranostic compound that effectively shrinks prostate tumor in mice. Theranostics is a cancer treatment that involves finding cancer cells anywhere in the body and ...
Comments
Post a Comment